Inhibicion de la Angiogénesis en pTNEs - page 15

Sunitinib en pTNEs G1/G2
Raymond E, et al. N Eng J Med 2011
The RECIST-defined ORR in patients receiving sunitinib was 9.3%; however, the majority
of patients had some degree of tumour shrinkage (Clinical Benefit Rate 72%) †
PR: ≥30% decrease
PD: ≥20% increase
Sunitinib Placebo
Confirmed partial or complete response
−100
−80
−60
−40
−20
0
20
40
60
Change from baseline (%)